@climateguy

Here is a conversation with Paul F. Schellhammer, MD, FACS and Richard Wassersug, PhD—two respected leaders who speak not only as experts, but as men living with prostate cancer.
They take a straightforward look at transdermal estradiol for androgen deprivation therapy (ADT), discussing the clinical evidence, quality-of-life considerations, and the importance of making informed treatment decisions with your healthcare team.